In tumor cells, Nrf2 is usually activated by ROS-induced oncogenes, such as KRAS and c-MYC (DeNicola, 2011), and inhibition of its activity may contribute to the apoptosis of tumor cells and abrogated tumor growth (Ryoo et al., 2016). This evidence concerns the gene MYC and neoplasm.